eligibility_summary
Eligible: 18–80, ECOG 0–1, >12‑wk survival, advanced/metastatic solid tumor after standard therapy failed/unavailable, tumor tissue, measurable disease, adequate marrow/renal/hepatic/cardiac/QTc, neg pregnancy test, contraception. Exclude: recent anti‑cancer/other trial therapy, uncontrolled effusions/CNS mets, major CV disease, uncontrolled DM/HTN/ILD, active HBV/HCV/HIV/syphilis, recent steroids, live vaccines, or major surgery, unresolved >G1 AEs, per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: ILB-3101, a fully humanized IgG1 antibody-drug conjugate (ADC). Mechanism: the monoclonal antibody binds B7-H3 on tumor cells, upon binding, the ADC is internalized and releases a cytotoxic payload, leading to selective killing of B7‑H3–expressing cells. Type: targeted biologic (ADC). Targeted cells/pathway: B7-H3 (CD276), a B7 family immune-regulatory ligand broadly overexpressed on many solid tumors, targets B7-H3–positive tumor cells across cancers (e.g., ovarian, SCLC, HNSCC, soft-tissue/uterine sarcoma, TNBC, ESCC, prostate). Trial: first-in-human, IV Q3W dose escalation/expansion assessing safety, PK, DLTs, MTD/MAD, and preliminary efficacy.